Iron deficiency anemia is common in children with end‐stage renal disease (ESRD) on long‐
term hemodialysis receiving erythropoiesis‐stimulating agents. One approach to maintain …

Initially, the optimal degree of anemia correction in patients with chronic kidney disease by
erythropoiesis-stimulating agents (ESAs) relied mainly on the results of observational …

Background: Iron overload can lead to organ and cell injuries. Although the mechanisms of
iron-induced cell damage have been extensively studied using various cells, little is known …

Background/Aim: More than half of deaths among hemodialysis patients are due to
cardiovascular disease. This study examined whether intravenous administration of ferric …

Background: Whether market competition influences health care provider responses to
national reimbursement reforms is unknown. Objectives: We examined whether changes in …

This work presents an update on the management of iron deficiency in patients with chronic
kidney disease (CKD), either with or without anaemia. A review is made of the …

In patients on chronic hemodialysis, there is no standard protocol for maintenance iron
supplementation. This study aimed to compare two fixed-dose intravenous (IV) iron …

Desidustat is a small molecule inhibitor of hypoxia-inducible factor-prolyl hydroxylase (HIF-
PH) discovered and developed by Zydus Lifesciences for the treatment of anemia …

Objective Iron supplementation and erythropoietin stimulating agents (ESAs) are essential
for maintaining hemoglobin levels in hemodialysis patients. However, patients with …

Iron deficiency (ID) occurs at high frequency across the spectrum of heart failure (HF), with
HF severity and race being potentially important predictors for its development. ID …